# Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)

> **NCT04127578** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Prevail Therapeutics** · enrollment: 32 (estimated)

## Conditions studied

- Parkinson Disease

## Interventions

- **BIOLOGICAL:** LY3884961
- **DRUG:** Methylprednisolone
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT04127578
- **Lead sponsor:** Prevail Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-01-03
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04127578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04127578, "Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04127578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*